| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0845 |
| Trial ID | ChiCTR2000028920 |
| Disease | Multiple Myeloma |
| Altered gene | CD19|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | To Evaluate the Efficacy and Safety of CD19, BCMA CAR-T Cell Immunotherapy for Relapse /Refractory Multiple Myeloma Patients: a Single Center, Single Arm, Open Clinical Trial. |
| Year | 2020 |
| Country | China |
| Company sponsor | The Third Affiliated Hospital of Kunming Medical University |
| Cohort 1 | |||||||
|
|||||||